CureVac stock downgraded to neutral by UBS after BioNTech acquisition – RP Digital

Business

CureVac stock downgraded to neutral by UBS after BioNTech acquisition

June 26, 20251 min0

CureVac stock downgraded to neutral by UBS after BioNTech acquisition

Source link

rpdigital

Leave a Reply Cancel reply

Related Articles

BancFirst declares quarterly dividend and trust interest payment

rpdigitalAugust 28, 20250

Jefferies raises Ollie's Bargain Outlet stock price target to $135 on strong growth

rpdigitalAugust 28, 20250